Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026

Arcus Biosciences, Inc. (RCUS)

NYSE Health Care Biotechnology S&P SmallCap 600
$18.28
+0.59 (+3.34%)
Close of Nov 06, 2026 · end-of-day data
Source: Arcus Biosciences, Inc.'s 10-K / 10-Q XBRL data on SEC EDGAR · fetched Nov 05, 2026

Revenue, net income & free cash flow

Income statement

fiscal years · USD
Fiscal yearFY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue$1.41M$8.35M$15.00M$78.00M$383.00M$38.00M$37.00M$51.00M$33.00M
Research & development$47.22M$49.65M$78.48M$159.00M$257.00M$288.00M$340.00M$448.00M$523.00M
Operating income-$53.44M-$54.86M-$88.71M-$124.00M$54.00M-$280.00M-$340.00M-$330.00M-$386.00M
Interest expense—————$2.00M$2.00M$4.00M$8.00M
Pre-tax income——-$84.71M-$123.00M$55.00M-$266.00M-$301.00M-$282.00M-$353.00M
Income tax————$2.00M$1.00M$6.00M$1.00M$0
Net income-$53.08M-$49.59M-$84.71M-$123.00M$53.00M-$267.00M-$307.00M-$283.00M-$353.00M
EBITDA-$50.83M-$51.20M-$85.13M-$121.00M$58.00M-$274.00M-$332.00M-$320.00M-$376.00M
EPS (basic)$-29.03$-1.43$-1.93$-2.24$0.76$-3.71$-4.15$-3.14$-3.29
EPS (diluted)$-29.03$-1.43$-1.93$-2.24$0.71$-3.71$-4.15$-3.14$-3.29
Diluted shares1.83M34.62M43.83M54.80M74.00M72.00M74.00M90.10M107.40M
Operating margin-3782.1%-656.8%-591.4%-159.0%14.1%-736.8%-918.9%-647.1%-1169.7%
Net margin-3756.7%-593.7%-564.7%-157.7%13.8%-702.6%-829.7%-554.9%-1069.7%

Balance sheet

fiscal years · USD
Fiscal yearFY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$98.43M$71.06M$57.94M$173.41M$148.00M$206.00M$127.00M$150.00M$222.00M
Short-term investments———$555.23M$351.00M$803.00M$632.00M$828.00M$759.00M
Total current assets$176.87M$258.95M$192.71M$735.82M$1.26B$1.07B$831.00M$1.02B$1.01B
Total assets$190.49M$274.93M$203.11M$772.29M$1.59B$1.34B$1.09B$1.15B$1.14B
Total current liabilities$12.73M$16.93M$22.71M$121.67M$166.00M$193.00M$184.00M$226.00M$231.00M
Long-term debt——————$0$48.00M$99.00M
Total debt——————$0$48.00M$99.00M
Total liabilities$36.62M$39.98M$39.27M$269.99M$750.45M$688.00M$633.00M$665.00M$508.00M
Shareholders' equity-$72.33M$234.94M$164.00M$502.00M$842.00M$657.00M$462.00M$485.00M$631.00M

Cash flow

fiscal years · USD
Fiscal yearFY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-$25.06M-$43.00M-$73.46M$111.00M-$256.00M$438.00M-$306.00M-$170.00M-$482.00M
Capital expenditures$5.51M$3.74M$1.93M$3.00M$26.00M$6.00M$24.00M$6.00M$2.00M
Free cash flow-$30.57M-$46.74M-$75.39M$108.00M-$282.00M$432.00M-$330.00M-$176.00M-$484.00M
Investing cash flow-$49.07M-$113.44M$59.21M-$434.00M-$4.00M-$413.00M$194.00M-$84.00M$66.00M
Financing cash flow$107.40M$129.07M$1.12M$439.00M$237.00M$33.00M$33.00M$277.00M$488.00M
Share buybacks—$0$94.00K——————
Stock-based compensation$495.00K$3.87M$8.98M$22.00M$55.00M$65.00M$73.00M$76.00M$60.00M
Depreciation & amortization$2.61M$3.66M$3.58M$3.00M$4.00M$6.00M$8.00M$10.00M$10.00M

Quarterly figures are rebuilt from the year-to-date totals companies report — Q4 is the full year minus the first nine months, since no 10-Q is filed for it. Values are as filed; later restatements replace earlier ones. Fiscal years are labelled by the calendar year in which they end.